Breaking News, Collaborations & Alliances

Innovent, Hutchison MediPharma in Drug Combo Collaboration

To evaluate Sintilimab and Fruquintinib in solid tumors

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Innovent Biologics, Inc. a China-based biopharmaceutical company has entered into a global collaboration agreement with Hutchison China MediTech to evaluate the safety and tolerability of Innovent’s sintilimab in combination with Hutchison MediPharma’s fruquintinib in patients with advanced solid tumors.    Innovent and Hutchison MediPharma will jointly explore potential application of this combination in solid tumors with global unmet medical needs through development efforts both...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters